Journal of Peking University(Health Sciences) ›› 2017, Vol. 49 ›› Issue (5): 910-914. doi: 10.3969/j.issn.1671-167X.2017.05.030
• Article • Previous Articles Next Articles
YU Jian-feng1, 2, *, JIN Yue-bo1, *, HE Jing1, AN Yuan1, LI Zhan-guo1
CLC Number:
[1] Kohno N, Awaya Y, Oyama T, et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease[J]. Am Rev Respir Dis, 1993, 148(3): 637-642. [2] Bandoh S, Fujita J, Ohtsuki Y, et al. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis[J]. Ann Rheum Dis, 2000, 59(4): 257-262. [3] Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease[J]. Am J Respir Crit Care Med, 2001, 164(7): 1182-1185. [4] Marie I, Hachulla E, Chérin P, et al. Interstitial lung disease in polymyositis and dermatomyositis[J]. Arthritis Rheum, 2002, 47(6): 614-622. [5] Nukiwa T. The role of biomarkers in management of interstitial lung disease: implication of biomarkers derived from type Ⅱ pneumocytes[M]// Du Bois RM, Richeldi L, editors. The European respiratory monograph 46 interstitial lung disease[M]. Leeds: Maney Publishing, 2009: 47-66. [6] Fathi M, Barbasso Helmers S, Lundberg IE. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis[J]. J Intern Med, 2012, 271(6): 589-597. [7] Hu Y, Wang LS, Jin YP, et al. Serum Krebs von den Lungen-6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients[J]. Clin Respir J, 2017, 11(3): 337-345. [8] Ohshimo S, Ishikawa N, Horimasu Y, et al. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis[J]. Respir Med, 2014, 108(7): 1031-1039. [9] Honda K, Okada F, Ando Y, et al. Comparison of pulmonary thin section CT findings and serum KL-6 levels in patients with sarcoi-dosis[J]. Br J Radiol, 2011, 84(999): 229-235. [10] Kinoshita F, Hamano H, Harada H, et al. Role of KL-6 in eva-luating the disease severity of rheumatoid lung disease:comparison with HRCT[J].Respir Med, 2004, 98(11): 1131-1137. [11] Chen F, Lu X, Shu X, et al. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study[J]. Intern Med J, 2015, 45(6): 641-647. [12] Janssen R, Kruit A, Grutters JC, et al. The mucin-1 568 adenosine to guanine polymorphism influences serum Krebs von den Lungen-6 levels[J]. Am J Respir Cell Mol Biol, 2006, 34(4): 496-499. [13] Ishikawa N, Hattori N, Yokoyama A, et al. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases[J]. Respir Investig, 2012, 50(1): 3-13. |
[1] | Zhanhong LAI,Jiachen LI,Zelin YUN,Yonggang ZHANG,Hao ZHANG,Xiaoyan XING,Miao SHAO,Yuebo JIN,Naidi WANG,Yimin LI,Yuhui LI,Zhanguo LI. A unicenter real-world study of the correlation factors for complete clinical response in idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 284-292. |
[2] | Qi WU,Yue-ming CAI,Juan HE,Wen-di HUANG,Qing-wen WANG. Correlation between dyslipidemia and rheumatoid arthritis associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 982-992. |
[3] | Wen-gen LI,Xiao-dong GU,Rui-qiang WENG,Su-dong LIU,Chao CHEN. Expression and clinical significance of plasma exosomal miR-34-5p and miR-142-3p in systemic sclerosis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1022-1027. |
[4] | Xiao-yan XING,Jun-xiao ZHANG,Feng-yun-zhi ZHU,Yi-fan WANG,Xin-yao ZHOU,Yu-hui LI. Clinical analysis of 5 cases of dermatomyositis complicated with macrophage activation syndrome [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1214-1218. |
[5] | ZHANG Pu-li,YANG Hong-xia,ZHANG Li-ning,GE Yong-peng,PENG Qing-lin,WANG Guo-chun,LU Xin. Value of serum YKL-40 in the diagnosis of anti-MDA5-positive patients with dermatomyositis complicated with severe pulmonary injury [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1055-1060. |
[6] | ZHU Yi-ying,MIN Sai-nan,YU Guang-yan. Effect of topical injection of cyclosporine A on saliva secretion and inflammation in the submandibular gland of non-obese diabetic mice [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 750-757. |
[7] | XIA Fang-fang,LU Fu-ai,LV Hui-min,YANG Guo-an,LIU Yuan. Clinical characteristics and related factors of systemic lupus erythematosus with interstitial pneumonia [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 266-272. |
[8] | Yu-zhou GAN,Yu-hui LI,Li-hua ZHANG,Lin MA,Wen-wen HE,Yue-bo JIN,Yuan AN,Zhan-guo LI,Hua YE. Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1001-1008. |
[9] | Jing XU,Jing XU,He LI,Jie TANG,Jian-long SHU,Jing ZHANG,Lian-jie SHI,Sheng-guang LI. Dermatomyositis combined with IgA vasculitis: A case report [J]. Journal of Peking University(Health Sciences), 2019, 51(6): 1173-1177. |
[10] | Yi-ying YANG,Xiao-xia ZUO,Hong-lin ZHU,Si-jia LIU. Advances in epigenetic markers of dermatomyositis/polymyositis [J]. Journal of Peking University(Health Sciences), 2019, 51(2): 374-377. |
[11] | LIU Shuang, AN Yuan, JIA Yuan, LI Zhan-Guo. A case of clinical overlap syndrome of rheumatoid arthritis and amyopathic dermatomyositis with multiple pulmonary injuries [J]. Journal of Peking University(Health Sciences), 2014, 46(5): 805-808. |
|